News ICON Public Limited Company

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 11/07/2025 BST			5-day change	1st Jan Change
150.52 ^USD	-1.02%		+0.28%	-28.22%

07-09	Truist Trims Price Target on ICON to $187 From $190, Keeps Buy Rating	MT
05-23	Trump's Tariff Blitz Roils Markets, Targets EU and Apple

Truist Trims Price Target on ICON to $187 From $190, Keeps Buy Rating	07-09	MT
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability	07-07	BU
ICON plc Schedules Second Quarter 2025 Earnings Conference Call	06-23	BU
ICON Public : plc 2025 AGM Notice and Proxy Materials	06-11	PU
ICON Public : plc 2024 IFRS Annual Report	06-11	PU
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm	06-02	BU
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm	06-02	PR
ICLR Shareholders Have the Right to Lead the ICON Public Limited Company Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ICLR	06-02	PR
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm	05-28	PR
ICON plc to Present at the William Blair 45th Annual Growth Stock Conference	05-27	BU
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm	05-23	PR
Trump's Tariff Blitz Roils Markets, Targets EU and Apple	05-23
Analyst recommendations: Crowdstrike, AMD, Boeing, Intuit, Okta…	05-23
ICON releases its ICON Cares 2024 Report	05-19	BU
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm	05-16	PR
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies	05-07	BU
Truist Securities Adjusts Price Target on ICON to $190 From $208, Keeps Buy Rating	05-05	MT
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall LAW FIRM	05-05	PR
Deutsche Bank Adjusts ICON Price Target to $200 From $235, Maintains Buy Rating	05-01	MT
ICON Seeks M&A Opportunities	05-01	CI
ICON Public Limited Company, Q1 2025 Earnings Call, May 01, 2025	05-01
Icon Q1 Adjusted Earnings, Revenue Fall	04-30	MT
ICON Public : Q1 2025 Press Release final	04-30	PU
Icon PLC: Q1 Earnings Snapshot	04-30	AQ
Icon Reports First Quarter 2025 Results	04-30	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ICON Public Limited Company

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Filters